PROMOMED took the first place among pharmaceutical companies in the media according to Medialogy

PROMOMED took the first place among pharmaceutical companies in the media INDEX in the annual Medialogy survey "Digital & PR Index: Pharmaceuticals 2025". The company maintained its leadership for the second year in a row and showed the highest result in the industry.

The study is based on the analysis of mentions of the leading players of the pharmaceutical market in the messages of more than 110 thousand. Mass media and 4 billion social media accounts for the period from January 1 to December 31, 2025. The media index reflects not only the number of publications, but also the quality of the company's presence in the information field: the influence of sources, the tone of messages, the role in the material, the presence of direct speech and the visibility of publications.

PROMOMED's position in the rating is confirmed by several key metrics at once. The company became the first in the media index among pharmaceutical companies in the media, the third in the number of reports, the first in the number of mentions in the main role, as well as the first in citations. The combination of these indicators suggests that PROMOMED acted in the media market not as a secondary participant in the industry, but as one of the main sources of news relevant to the market.

Separately, the study captures strong positions in social networks. In the ranking of pharmaceutical companies according to the CM Index, PROMOMED took the second place among all participants and the first place among Russian pharmaceutical companies, rising by three positions compared to the previous year. The metric reflects the quality of the brand's information field in social media and takes into account the influence of authors, platforms and audience involvement in the discussion of messages.

Among the key information events, the authors of the study note the entry into the market of the drug Tirzetta®, the first domestic tirzepatide, permission from the Government of the Russian Federation for the Company to release the drugs Quincenta® and Velgia® by the end of 2026 without the consent of the copyright holder, as well as news related to business development and capitalization.

PROMOMED's leadership in the Medialogy rating reflects the Company's systematic efforts to develop the Russian pharmaceutical market and increase the availability of modern pharmaceutical solutions. The Company's presence in the information field is due to news about production, scientific and technological development, the launch of drugs and participation in solving urgent healthcare problems. It is precisely such topics that generate sustained media and social media attention, as they are directly related to the needs of patients, doctors, the government, and the pharmaceutical industry.